[go: up one dir, main page]

AR134155A2 - Inhibidores de malt-1 de tiazolo[5,4-b]piridina - Google Patents

Inhibidores de malt-1 de tiazolo[5,4-b]piridina

Info

Publication number
AR134155A2
AR134155A2 ARP240102836A ARP240102836A AR134155A2 AR 134155 A2 AR134155 A2 AR 134155A2 AR P240102836 A ARP240102836 A AR P240102836A AR P240102836 A ARP240102836 A AR P240102836A AR 134155 A2 AR134155 A2 AR 134155A2
Authority
AR
Argentina
Prior art keywords
thiazolo
malt
pyridine
inhibitors
ring
Prior art date
Application number
ARP240102836A
Other languages
English (en)
Inventor
Puneet Kumar
Anthony Mastracchio
Mark Mills
Andrew William Phillips
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of AR134155A2 publication Critical patent/AR134155A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación proporciona compuestos de la fórmula general (1) en donde R¹ᵃ, R¹ᵇ, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ y el anillo A tienen cualquiera de los valores definidos en la memoria descriptiva, y sales aceptables desde el punto de vista farmacéutico de estos.
ARP240102836A 2022-03-31 2024-10-21 Inhibidores de malt-1 de tiazolo[5,4-b]piridina AR134155A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263362302P 2022-03-31 2022-03-31

Publications (1)

Publication Number Publication Date
AR134155A2 true AR134155A2 (es) 2025-12-10

Family

ID=86185307

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP230100771A AR128917A1 (es) 2022-03-31 2023-03-29 Inhibidores de malt-1 de tiazolo[5,4-b]piridina
ARP240102836A AR134155A2 (es) 2022-03-31 2024-10-21 Inhibidores de malt-1 de tiazolo[5,4-b]piridina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP230100771A AR128917A1 (es) 2022-03-31 2023-03-29 Inhibidores de malt-1 de tiazolo[5,4-b]piridina

Country Status (13)

Country Link
US (2) US11993613B2 (es)
EP (1) EP4499650A1 (es)
JP (2) JP7723030B2 (es)
KR (1) KR20240168420A (es)
CN (1) CN119855821A (es)
AR (2) AR128917A1 (es)
AU (1) AU2023243460A1 (es)
CA (1) CA3246085A1 (es)
CO (1) CO2024014618A2 (es)
IL (1) IL316288A (es)
MX (1) MX2024012018A (es)
TW (1) TW202345806A (es)
WO (1) WO2023192913A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑
WO2025223516A1 (zh) * 2024-04-24 2025-10-30 首药控股(北京)股份有限公司 一种抑制剂杂环化合物

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2496666A1 (fr) 1980-12-22 1982-06-25 Ici Pharma Nouveaux derives de cephalosporine et composition pharmaceutique les contenant
US5851741A (en) 1986-01-24 1998-12-22 Fuji Photo Film Co., Ltd. Method for the formation of color images
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5646128A (en) 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5795977A (en) 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
EP0929553B1 (en) 1996-10-02 2005-03-16 Novartis AG Pyrimidine derivatives and processes for the preparation thereof
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
US6608058B2 (en) 2000-04-17 2003-08-19 Dong Wha Pharm. Ind. Co., Ltd. 6-methylnicotinamide derivatives as antiviral agents
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
AU2003293409A1 (en) 2002-12-09 2004-06-30 Karl K. Johe Method for discovering neurogenic agents
SE0400284D0 (sv) 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
JP2006241089A (ja) 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
KR20070052207A (ko) 2005-11-16 2007-05-21 주식회사 엘지생명과학 신규한 ｋｄｒ 억제제
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
MX2009006234A (es) 2006-12-11 2009-06-22 Wyeth Corp Moduladores del canal de ion.
EA200900819A1 (ru) 2006-12-22 2010-02-26 Новартис Аг Хиназолины для ингибирования pdk1
JP5219583B2 (ja) 2008-03-31 2013-06-26 住友化学株式会社 組成物、光学フィルムとその製造方法、光学部材及び表示装置
JP5219594B2 (ja) 2008-04-08 2013-06-26 住友化学株式会社 組成物、光学フィルム及びフラットパネル表示装置
US20100121052A1 (en) 2008-06-20 2010-05-13 Rama Jain Novel compounds for treating proliferative diseases
UY31984A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.
JP5443720B2 (ja) 2008-09-05 2014-03-19 住友化学株式会社 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置
KR101699991B1 (ko) 2009-02-11 2017-01-26 메르크 파텐트 게엠베하 신규의 아미노 아자헤테로시클릭 카르복사미드
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
ES2632220T3 (es) 2009-06-15 2017-09-11 Rigel Pharmaceuticals, Inc. Inhibidores de moléculas pequeñas de tirosina cinasa del bazo (SYK)
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CN102713618B (zh) 2009-09-16 2015-07-15 新基阿维罗米克斯研究公司 蛋白激酶复合物和抑制剂
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
PT2730564T (pt) 2010-11-19 2018-07-24 Ligand Pharm Inc Aminas heterocíclicas e suas utilizações
WO2012075232A1 (en) 2010-12-04 2012-06-07 Trevena, Inc. Opioid receptor ligands and methods of using and making the same
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
US8674113B2 (en) 2010-12-10 2014-03-18 Boehringer Ingelheim International Gmbh Compounds
WO2013038308A1 (en) 2011-09-15 2013-03-21 Glenmark Pharmaceuticals S.A. SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS
ES2657955T3 (es) 2012-04-17 2018-03-07 Fujifilm Corporation Compuesto heterocíclico que contiene nitrógeno o sal del mismo
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
EP2935261A1 (de) 2012-12-20 2015-10-28 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische dihydrochinoxalinone
WO2014146246A1 (en) 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors
WO2016027904A1 (ja) 2014-08-22 2016-02-25 富士フイルム株式会社 Ｆｌｔ３変異陽性癌を処置するための医薬組成物、変異型ｆｌｔ３阻害剤およびそれらの応用
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
US10351548B2 (en) 2015-06-11 2019-07-16 International Society For Drug Development S.R.L. 2-oxo-1,2-dihydropyridine-3-carboxamide compounds and their use as inhibitors of PDK1
EP3350158A4 (en) 2015-09-16 2019-05-08 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CA3000709A1 (en) 2015-10-01 2017-04-06 Memorial Sloan-Kettering Cancer Center Inhibitors of menaquinone biosynthesis
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
GB201603311D0 (en) 2016-02-25 2016-04-13 Jakobsson Per Johan New uses and methods
US10933068B2 (en) 2016-05-26 2021-03-02 Sonic Master Limited Modulators of DUX4 for regulation of muscle function
CA3032334A1 (en) 2016-07-29 2018-02-01 Lupin Limited Substituted thiazolo-pyridine compounds as malt1 inhibitors
WO2018112077A1 (en) 2016-12-13 2018-06-21 Centaurus Therapeutics Inhibitors of dihydroceramide desaturase for treating disease
US11542233B2 (en) 2016-12-23 2023-01-03 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
WO2018226150A1 (en) 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors
WO2018228475A1 (zh) 2017-06-14 2018-12-20 正大天晴药业集团股份有限公司 Syk抑制剂及其使用方法
CN110709402B (zh) 2017-06-15 2022-05-10 浙江海正药业股份有限公司 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途
WO2019090198A1 (en) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
US10844044B2 (en) 2018-06-14 2020-11-24 Vanderbilt University WDR5 inhibitors and modulators
WO2020031107A1 (en) 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2020051571A1 (en) 2018-09-07 2020-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Brd4-jak2 inhibitors
EP3898630B1 (en) 2018-12-17 2023-05-10 F. Hoffmann-La Roche AG Novel imidazopyrazine derivatives
CN112409331B (zh) 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
EP4041230A4 (en) 2019-10-07 2023-11-01 D.E. Shaw Research, LLC AROMATIC ARYLMETHYLENE COMPOUNDS AS BLOCKERS OF KV1.3 POTASSIUM AGITATOR CHANNELS
GB201914910D0 (en) 2019-10-15 2019-11-27 Sentinel Oncology Ltd Pharmaceutical compounds
WO2021175200A1 (en) 2020-03-02 2021-09-10 Sironax Ltd Ferroptosis inhibitors–diarylamine para-acetamides
CN113527291B (zh) 2020-04-13 2025-07-22 广东东阳光药业股份有限公司 Ret抑制剂、其药物组合物及其用途
JP2023540270A (ja) 2020-08-28 2023-09-22 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環式化合物およびその使用
EP4216946A4 (en) 2020-09-23 2024-11-13 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
WO2022081995A1 (en) 2020-10-16 2022-04-21 Rheos Medicines, Inc. Malt1 modulators and uses thereof
CN116916924A (zh) 2020-10-16 2023-10-20 稀有生物科学股份有限公司 Malt1调节剂及其用途
TW202233580A (zh) 2020-10-30 2022-09-01 美商嘉來克生命科學有限責任公司 整合應激路徑之調節劑
GB202018412D0 (en) 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑

Also Published As

Publication number Publication date
CO2024014618A2 (es) 2024-11-08
WO2023192913A1 (en) 2023-10-05
US11993613B2 (en) 2024-05-28
AU2023243460A1 (en) 2024-10-24
TW202345806A (zh) 2023-12-01
JP7723030B2 (ja) 2025-08-13
US20250084099A1 (en) 2025-03-13
KR20240168420A (ko) 2024-11-29
US20230312601A1 (en) 2023-10-05
CA3246085A1 (en) 2023-10-05
JP2025156455A (ja) 2025-10-14
CN119855821A (zh) 2025-04-18
JP2023152927A (ja) 2023-10-17
MX2024012018A (es) 2024-11-08
AR128917A1 (es) 2024-06-26
IL316288A (en) 2024-12-01
EP4499650A1 (en) 2025-02-05

Similar Documents

Publication Publication Date Title
AR134155A2 (es) Inhibidores de malt-1 de tiazolo[5,4-b]piridina
AR110753A1 (es) Inhibidores selectivos de jak1
CL2022001513A1 (es) Inhibidores de kras g12c
AR126255A1 (es) Derivados de imidazotriazina como moduladores de il-17
MX2022001908A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina.
MX2022003276A (es) Derivados de indol e indazol sulfonamido sustituidos en la posicion 4 como inhibidores de parg.
AR027518A1 (es) Inhibidores de girasas y usos de los mismos
AR114044A1 (es) Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central
AR096846A1 (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet
MX2019015226A (es) Inhibidores de quinasa alk2 que contienen imidazol.
MX392515B (es) Compuestos inhibidores de beta-lactamasa
AR128846A1 (es) Compuestos de indazol sustituidos con piperazina como inhibidores de parg
AR119910A1 (es) DERIVADOS DE 4,4a,5,7,8,8a-HEXAHIDROPIRIDO[4,3-b][1,4]OXAZIN-3-ONA COMO INHIBIDORES DE MAGL
CY1114767T1 (el) Ν,ν-υποκατεστημενες ενωσεις 3-αμινοπυρρολιδινης χρησιμες ως αναστολεις επαναπροσληψης μονοαμινων
MX2019013260A (es) Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas.
AR042956A1 (es) Inhibidores de girasa y usos de los mismos
AR039648A1 (es) Compuestos de aril cetona pirrolo triazina utiles como inhibidores de cinasa y las composiciones farmaceuticas que las contienen
AR089489A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
MX2019009354A (es) Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer.
MX2019009351A (es) Piridinas sustituidas con heteroarilsulfonilo y su uso en el tratamiento del cancer.
PE20231097A1 (es) Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso
AR121878A1 (es) DERIVADOS DE BENZODIAZEPINA COMO PAM DE GABAA g1
ECSP23080267A (es) Compuestos de lactivicina, su preparación y uso como agentes antibacterianos
CO2023017975A2 (es) Inhibidores de alk2 quinasa que contienen imidazol
CO2024009334A2 (es) Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2h-pirrolo[3',2':5,6]pirido[2,3-b][1,4]oxazepina